niacinamide has been researched along with Angiosarcoma in 8 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sorafenib showed limited antitumor activity in pretreated patients only, for both visceral and superficial angiosarcoma, but tumor control was of short duration." | 9.16 | Sorafenib for patients with advanced angiosarcoma: a phase II Trial from the French Sarcoma Group (GSF/GETO). ( Bay, JO; Blay, JY; Bompas, E; Bousquet, G; Chevreau, C; Clisant, S; Collard, O; Cupissol, D; Fournier, C; Gauthier, E; Isambert, N; Italiano, A; Le Cesne, A; Lemaitre, L; Penel, N; Piperno-Neumann, S; Ray-Coquard, I; Robin, YM, 2012) |
| "We have carried out a stratified phase II study of sorafenib (So) in patients with advanced angiosarcoma (n = 32) and epithelioid hemangioendothelioma (n = 13)." | 5.19 | Low level of baseline circulating VEGF-A is associated with better outcome in patients with vascular sarcomas receiving sorafenib: an ancillary study from a phase II trial. ( Bal-Mahieu, C; Baldeyrou, B; Bay, JO; Blay, JY; Bompas, E; Chevreau, C; Clisant, S; Fournier, C; Italiano, A; Lansiaux, A; Le Cesne, A; Penel, N; Piperno-Neumann, S; Ray-Coquard, I; Robin, YM, 2014) |
| "Sorafenib showed limited antitumor activity in pretreated patients only, for both visceral and superficial angiosarcoma, but tumor control was of short duration." | 5.16 | Sorafenib for patients with advanced angiosarcoma: a phase II Trial from the French Sarcoma Group (GSF/GETO). ( Bay, JO; Blay, JY; Bompas, E; Bousquet, G; Chevreau, C; Clisant, S; Collard, O; Cupissol, D; Fournier, C; Gauthier, E; Isambert, N; Italiano, A; Le Cesne, A; Lemaitre, L; Penel, N; Piperno-Neumann, S; Ray-Coquard, I; Robin, YM, 2012) |
| "Angiosarcoma is a rare neoplasm of endothelial origin that has limited treatment options and poor five-year survival." | 1.39 | Pharmacologic inhibition of MEK signaling prevents growth of canine hemangiosarcoma. ( Andersen, NJ; Baker, LH; Boguslawski, EA; Dawes, MJ; Duesbery, NS; Dykema, KJ; Froman, RE; Furge, KA; Kamstock, DA; Kitchell, BE; Krivochenitser, RI; Nickoloff, BJ; Thomas, DG, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andersen, NJ | 1 |
| Nickoloff, BJ | 1 |
| Dykema, KJ | 1 |
| Boguslawski, EA | 1 |
| Krivochenitser, RI | 1 |
| Froman, RE | 1 |
| Dawes, MJ | 1 |
| Baker, LH | 1 |
| Thomas, DG | 1 |
| Kamstock, DA | 1 |
| Kitchell, BE | 1 |
| Furge, KA | 1 |
| Duesbery, NS | 1 |
| Penel, N | 2 |
| Ray-Coquard, I | 2 |
| Bal-Mahieu, C | 1 |
| Chevreau, C | 2 |
| Le Cesne, A | 2 |
| Italiano, A | 2 |
| Bompas, E | 2 |
| Clisant, S | 2 |
| Baldeyrou, B | 1 |
| Lansiaux, A | 1 |
| Robin, YM | 2 |
| Bay, JO | 2 |
| Piperno-Neumann, S | 2 |
| Blay, JY | 2 |
| Fournier, C | 2 |
| Rothweiler, S | 1 |
| Dill, MT | 1 |
| Terracciano, L | 1 |
| Makowska, Z | 1 |
| Quagliata, L | 1 |
| Hlushchuk, R | 1 |
| Djonov, V | 1 |
| Heim, MH | 1 |
| Semela, D | 1 |
| Donghi, D | 1 |
| Dummer, R | 1 |
| Cozzio, A | 1 |
| Sleijfer, S | 1 |
| Bousquet, G | 1 |
| Isambert, N | 1 |
| Lemaitre, L | 1 |
| Gauthier, E | 1 |
| Collard, O | 1 |
| Cupissol, D | 1 |
| Tamiya, H | 1 |
| Kamo, R | 1 |
| Kumei, A | 1 |
| Yanagihara, S | 1 |
| Ishii, M | 1 |
| Kobayashi, H | 1 |
| Ono, S | 1 |
| Tanioka, M | 1 |
| Fujisawa, A | 1 |
| Tanizaki, H | 1 |
| Miyachi, Y | 1 |
| Matsumura, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II Multicenter Stratified Study Evaluating the Efficacy and Toxicity of Sorafenib in Treating Locally Advanced or Metastatic Angiosarcomas That Are Not Accessible to Curative Surgery[NCT00874874] | Phase 2 | 96 participants (Anticipated) | Interventional | 2008-05-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for niacinamide and Angiosarcoma
| Article | Year |
|---|---|
Low level of baseline circulating VEGF-A is associated with better outcome in patients with vascular sarcomas receiving sorafenib: an ancillary study from a phase II trial.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Enzyme-Linked Immunosorbent Assay; Hemangioendothelioma, E | 2014 |
Sorafenib for patients with advanced angiosarcoma: a phase II Trial from the French Sarcoma Group (GSF/GETO).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Endpoint Determination; Fe | 2012 |
6 other studies available for niacinamide and Angiosarcoma
| Article | Year |
|---|---|
Pharmacologic inhibition of MEK signaling prevents growth of canine hemangiosarcoma.
Topics: Animals; Antineoplastic Agents; Benzamides; Cell Proliferation; Diphenylamine; Disease Models, Anima | 2013 |
Generation of a murine hepatic angiosarcoma cell line and reproducible mouse tumor model.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Di | 2015 |
Complete remission in a patient with multifocal metastatic cutaneous angiosarcoma with a combination of paclitaxel and sorafenib.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Head and Neck Neoplasms; He | 2010 |
Phase II studies in soft tissue sarcoma: time for reappraisal.
Topics: Antineoplastic Agents; Benzenesulfonates; Female; Hemangiosarcoma; Humans; Male; Niacinamide; Phenyl | 2012 |
Partial response of angiosarcoma of the scalp to sorafenib: association with decreased expression of vascular endothelial growth factors and their receptors.
Topics: Antineoplastic Agents; Head and Neck Neoplasms; Hemangiosarcoma; Humans; Male; Middle Aged; Niacinam | 2012 |
Angiosarcoma of the scalp successfully treated with a single therapy of sorafenib.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Female; Head and Neck Neoplasms; Hemangiosarcoma; Hu | 2012 |